Zenas Biopharma earnings were -$484.4M for the trailing 12 months ending Jun 30, 2026, with N/A growth year over year. The latest ZBIO earnings report on Jun 30, 2026 announced Q2 2026 earnings of -$111.5M, up 37.6% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, ZBIO reported annual earnings of -$377.7M, with 140.6% growth.
What were Zenas Biopharma's earnings last quarter?
On ZBIO's earnings call on Aug 11, 2026, Zenas Biopharma (NASDAQ: ZBIO) reported Q2 2026 earnings per share (EPS) of -$1.77, up 41.6% year over year. Total ZBIO earnings for the quarter were -$111.46 million. In the same quarter last year, Zenas Biopharma's earnings per share (EPS) was -$1.25.
As of the last Zenas Biopharma earnings report, Zenas Biopharma is currently losing money. Zenas Biopharma's net profit (also called net income) for the twelve months ending Jun 30, 2026 was -$484.38 million, a 173.65% increase year over year.
What was ZBIO's earnings growth in the past year?
As of Zenas Biopharma's earnings date in Aug 11, 2026, Zenas Biopharma's earnings has grown year over year. ZBIO earnings in the past year totalled -$484.38 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.